Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro

Auranofin Attenuates Non-Alcoholic Fatty Liver Disease by Suppressing Lipid Accumulation and NLRP3 Inflammasome-Mediated Hepatic Inflammation In Vivo and In Vitro

Non-alcoholic fatty liver disease (NAFLD) causes liver dysfunction and is associated with obesity and type 2 diabetes. Chronic inflammation is associated not only with the development of NAFLD, but also with hepatic diseases, including steatohepatitis, cirrhosis, and hepatocellular carcinoma. Aurano...

Full description

Bibliographic Details
Main Authors: Hyun Hwangbo, Min Yeong Kim, Seon Yeong Ji, So Young Kim, Hyesook Lee, Gi-Young Kim, Cheol Park, Young-Sam Keum, Su Hyun Hong, Jaehun Cheong, Yung Hyun Choi
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Antioxidants
Subjects:
auranofin
NAFLD
hepatic inflammation
lipid accumulation
NLRP3 inflammasome
Online Access:https://www.mdpi.com/2076-3921/9/11/1040

Internet

https://www.mdpi.com/2076-3921/9/11/1040

Similar Items